BioCentury
ARTICLE | Company News

Celimmune licenses Amgen's celiac candidate

March 3, 2015 1:42 AM UTC

Amgen Inc. (NASDAQ:AMGN) granted Celimmune LLC (Bethesda, Md.) exclusive, worldwide rights outside of Japan to develop and commercialize AMG 714, a human mAb against IL-15. Amgen has an exclusive option to reacquire AMG 714 after Celimmune completes additional clinical trials. Both companies declined to disclose details of the deal, including financial terms.

Celimmune is planning Phase II trials of the candidate to treat diet non-responsive celiac disease and refractory celiac disease (RCD). The company declined to give a development timeline. ...